10-Q · May 15, 2026
Pasithea Therapeutics Corp. reported a net loss of $2.87 million for Q1 2026, which is an improvement compared to a net loss of $3.56 million in Q1 2025, indicating a 19.5% reduction in losses year-over-year. Research…
Earnings analysis · 10-Q
KTTA earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q text does not include the income statement, balance sheet, cash flow statement, MD&A, or segment disclosures, so revenue, margins, EPS, liquidity, and cash-flow trends cannot be assessed. Disclosure…
Read full summary
The extracted 10-Q text does not include the income statement, balance sheet, cash flow statement, MD&A, or segment disclosures, so revenue, margins, EPS, liquidity, and cash-flow trends cannot be assessed. Disclosure controls were deemed effective as of June 30, 2026, and no material internal-control changes were reported during the six months ended June 30, 2026. The company reported no material changes to the risk factors in its December 31, 2025 Form 10-K.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure Controls Deemed Effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026.
-
No Material Control Changes
The company reported no changes in internal control over financial reporting during the six months ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, those controls.
What to watch
-
Existing Risk Factors Remain
The filing states there were no material changes to the risk factors in the December 31, 2025 Form 10-K filed on March 30, 2026; the previously disclosed risks therefore remain applicable.
-
Limitations of Internal Controls
Management acknowledges that control systems provide only reasonable, not absolute, assurance and may not prevent or detect all errors or fraud.
Management's outlook
No quantitative revenue or EPS outlook was provided in the extracted 10-Q text; guidance was not provided.
Earlier filings 4
10-K · March 30, 2026
KTTA is a clinical-stage biotech focused on PAS-004, a macrocyclic MEK1/2 inhibitor aimed initially at NF1-PN and MAPK-driven tumors. Early clinical data through a December 26, 2025 cut-off show 34 patients dosed across…
10-Q · May 15, 2025
Pasithea reported a smaller net loss of $3,563,238 for Q1 2025 (EPS $(1.61)) versus a net loss of $3,860,840 in Q1 2024 (EPS $(3.70)), driven by lower operating expenses and a non-cash $76,867 favorable change in…
10-Q · November 13, 2024
Pasithea Therapeutics reported a Q3 GAAP net loss of $2,999,834 (loss per share $2.87) compared with a loss of $3,612,590 in Q3 2023, driven by lower G&A but continued R&D spend. Cash declined to $9.36M at September 30,…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.